KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:可得 入排置信度 0.45

Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial.

Zhiqiang Zhong, Hongjuan Lu, Ting Li, Lingying Ye, Ling Zhou, Xiaobing Wang, Xin Wu, Huji Xu

Front Immunol 17 1804751

PMID42416060
PMCIDPMC13337383
DOI10.3389/fimmu.2026.1804751
发表日期2026-07-08
入排依据:The study is a randomized Phase III trial of a drug (adalimumab or its biosimilar) in humans with a malignant-neoplasm-adjacent mesh term (Spondylitis, Ankylosing) but is not an oncology study. It also does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Patients with active ankylosing spondylitis (AS) exhibit substantial heterogeneity in their clinical responses to tumor necrosis factor alpha inhibitors (TNFi). Consensus clustering, an unsupervised cluster discovery method, may identify AS subgroups with more homogeneous treatment response patterns to adalimumab (ADA), a widely prescribed TNFi. METHODS: We performed longitudinal consensus clustering based on 8 repeated measurements of 10 core response variables in 438 patients with active AS enrolled in a 24-week phase III randomized controlled trial of ADA or its biosimilar, IBI303. Baseline characteristics and important endpoints-including the Assessment of SpondyloArthritis International Society (ASAS)-based and Ankylosing Spondylitis Disease Activity Score Inactive Disease (ASDAS)-based response criteria-were compared between the identified clusters. Predictive models of cluster membership reconstructed from data beyond week 2 were developed and internally validated to facilitate early, prospective identification of the clusters based on baseline and week-2 data. RESULTS: Two longitudinal clusters were characterized: a favorable-response cluster (C1, n = 246, 56.2%) and a less favorable-response cluster (C2, n = 192, 43.8%). Compared with C1, C2 was characterized by older age, longer disease duration, and more frequent prior TNFi exposure, despite comparable baseline C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). For the majority of clinical endpoints except CRP and BASMI, significant divergence emerged as early as week 2 and was sustained through week 24. For instance, C1 achieved significantly higher rates of ASDAS-Inactive Disease (ASDAS-ID) than C2 at week 2 (0.21 [95% CI 0.16, 0.26] vs. 0.01 [95% CI 0.00, 0.02]; Risk Difference [RD]: -0.21 [95% CI -0.26, -0.15], p < 0.001) and week 24 (0.63 [95% CI 0.57, 0.69] vs. 0.14 [95% CI 0.09, 0.18]; RD: -0.49 [95% CI -0.57, -0.42], p < 0.001). A multivariable model incorporating one baseline and eight week-2 variables had an optimism-corrected C-statistic of 0.880 [95% CI 0.859, 0.915] to correctly identify C2. CONCLUSIONS: These observed response trajectories exhibited distinct baseline characteristics and early response divergence at week 2. While these findings provide a hypothesis-generating framework for early patient stratification, their utility for prospective clinical patient triage requires further independent validation.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Diagnostic plots for determining the optimal number of clusters. Consensus matrix plot (A) , consensus cumulative distribution function (B) , and proportion of ambiguously clustered pairs (C) to determine the optimal number of clusters of different clustering with cluster numbers ranging from 2 to 5. Perfect criteria correspond to an ambiguous range of the open interval (0, 1), while relaxed criteria correspond to (0.1 to 0.9).
非 KM Figure
Figure 2Figure 2 Changes from baseline of continuous endpoints through week 24 in the C1 cluster (blue) and C2 cluster (red). Results from both mixed models for repeated measures (MMRM) (circles and solid lines) and complete case analysis (CCA, rectangles and dashed lines) are presented.
非 KM Figure
Figure 3Figure 3 Proportions of patients in the C1 cluster (red) and C2 cluster (blue) who achieved key response criteria, including ASAS-PR, ASAS20, ASAS40, ASAS5/6, ASDAS-CII, ASDAS-MI, and ASDAS-ID. Results from both non-responder imputation (NRI) (circles and solid lines) and complete case analysis (CCA, rectangles and dashed lines) are presented.
非 KM Figure
Figure 4Figure 4 Predictive model for the C2 cluster based on baseline and week 2 data, presented as a nomogram (A) and an online Shiny-based calculator (B) .
非 KM Figure